UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--------------------------------|-------------------------------|----------------------|---------------------|------------------|
| 10/542,281 | 07/15/2005 | Paul W Finn | BJS-620-379 | 5263 |
| 23117 NIXON & VA | 7590 03/13/200 NDERHYE, PC | EXAMINER | | |
| 901 NORTH G | LEBE ROAD, 11TH F | BARTS, SAMUEL A | | |
| ARLINGTON, VA 22203 | | | ART UNIT | PAPER NUMBER |
| | | | 1621 | |
| | | | | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 03/13/2008 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | Application No. | Applicant(s) | | |
|---|---|--|--|--|
| | 10/542,281 | FINN ET AL. | | |
| Office Action Summary | Examiner | Art Unit | | |
| | Samuel A. Barts | 1621 | | |
| The MAILING DATE of this communication appeariod for Reply | pears on the cover sheet with the c | correspondence address | | |
| A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). | NATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tirwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE | N. nely filed the mailing date of this communication. D (35 U.S.C. § 133). | | |
| Status | | | | |
| Responsive to communication(s) filed on 17 E This action is FINAL . 2b) ☑ This Since this application is in condition for allowate closed in accordance with the practice under E | s action is non-final. ince except for formal matters, pro | | | |
| Disposition of Claims | | | | |
| 4) Claim(s) 62-110 and 112-114 is/are pending in 4a) Of the above claim(s) is/are withdra 5) Claim(s) 62-110 is/are allowed. 6) Claim(s) 112-114 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o | wn from consideration. | | | |
| Application Papers | | | | |
| 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct to by the Example 2. | cepted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob | e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d). | | |
| Priority under 35 U.S.C. § 119 | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date | 4) Interview Summary Paper No(s)/Mail D: 5) Notice of Informal F 6) Other: | ate | | |

Application/Control Number: 10/542,281 Page 2

Art Unit: 1621

DETAILED ACTION

Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 113 -114 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for *inhibiting HDAC in subject comprising administering to a subject suffering from cancer or psoriasis and effective amount of compound according to claim 62,* , does not reasonably provide enablement for treatment of all cancers and psoriasis. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. The pathways for causing these maladies are two numerous and broadly diverse to reasonably expect that inhibiting a single mechanism would be sufficient to treat said maladies. For example, lung cancer is well known to be caused by smoking. Thus the administering of these compounds to a person who heavily smokes would not reasonably be expected to be useful in treating lung cancer. Moreover, these maladies have no recognized single cause. In fact, the aforementioned diseases are recognized as having many contributing factors, ranging from hereditary considerations, to lifestyle

Application/Control Number: 10/542,281 Page 3

Art Unit: 1621

choices such as the weight and diet of a person. There are many more factors as to why people are inflicted with these diseases.

3. Claim 112 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The treatment of all proliferative conditions on its face is incredible. It would be an undue burden to one having ordinary skill in the art to determine which compounds are suitable to treat a specific proliferative condition. The broadest definition of "prolifeative conditions" is: to grow by rapid production of new parts, cells, buds, or offspring. Thus the claims read on inhibiting life and normal cell growth. It would be an undue burden for an artisan having ordinary skill to determine which disease applicants intend to treat.

Applicant is respectfully requested to cancel this claim or recite of list of enabled proliferative condition in the claims.

Allowable Subject Matter

4. Claims 62-110 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel A. Barts whose telephone number is 571-272-2870. The examiner can normally be reached on 6:30-3:00.

Art Unit: 1621

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samuel A Barts/ Primary Examiner Art Unit 1621